Organization | BiondVax Pharmaceuticals

BiondVax Pharmaceuticals Report issue

For profit Phase 2 Phase 3

Founded: Ness Ziona HaMerkaz Israel (2003)

Status: Defunct (2018)

Organization Overview

First Clinical Trial

2009

NCT00877448

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Alternative names

BiondVax Pharmaceuticals ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

m-001 influenza vaccine (2 trials)

Drugs in Phase 2 Trials (9)

aluminum hydroxide (Gaviscon) (1 trial)

inactivated influenza vaccine (1 trial)

isa-51 (1 trial)

montanide isa 720 (1 trial)

multimeric-001 (5 trials)

phosphate (1 trial)

proglumide (1 trial)

sodium chloride (1 trial)

tivantinib (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Influenza, Human (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial APIs: 10